Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone734-845-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$290,000.00
Profitability
Miscellaneous
Employees32
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions
What is Millendo Therapeutics' stock symbol?
Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."
How were Millendo Therapeutics' earnings last quarter?
Millendo Therapeutics Inc (NASDAQ:MLND) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.07. View Millendo Therapeutics' Earnings History.
When is Millendo Therapeutics' next earnings date?
What price target have analysts set for MLND?
7 equities research analysts have issued twelve-month price objectives for Millendo Therapeutics' shares. Their forecasts range from $22.00 to $29.00. On average, they anticipate Millendo Therapeutics' share price to reach $25.14 in the next year. This suggests a possible upside of 241.2% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.
What is the consensus analysts' recommendation for Millendo Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.
Has Millendo Therapeutics been receiving favorable news coverage?
Headlines about MLND stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Millendo Therapeutics.
Are investors shorting Millendo Therapeutics?
Millendo Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 258,600 shares, an increase of 11.7% from the August 30th total of 231,500 shares. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is presently 7.6 days. Currently, 4.1% of the company's stock are sold short. View Millendo Therapeutics' Current Options Chain.
Who are some of Millendo Therapeutics' key competitors?
Some companies that are related to Millendo Therapeutics include Arcus Biosciences (RCUS), Syros Pharmaceuticals (SYRS), AMAG Pharmaceuticals (AMAG), Aurinia Pharmaceuticals (AUPH), BioSpecifics Technologies (BSTC), Merus (MRUS), XBiotech (XBIT), Obseva (OBSV), ImmunoGen (IMGN), DURECT (DRRX), Lexicon Pharmaceuticals (LXRX), Kadmon (KDMN), AC Immune (ACIU), Prothena (PRTA) and Kiniksa Pharmaceuticals (KNSA).
What other stocks do shareholders of Millendo Therapeutics own?
Who are Millendo Therapeutics' key executives?
Millendo Therapeutics' management team includes the folowing people:
- Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)
- Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
- Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
- Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
- Dr. Pharis Mohideen, Chief Medical Officer (Age 54)
How do I buy shares of Millendo Therapeutics?
Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Millendo Therapeutics' stock price today?
One share of MLND stock can currently be purchased for approximately $7.37.
How big of a company is Millendo Therapeutics?
Millendo Therapeutics has a market capitalization of $98.83 million and generates $290,000.00 in revenue each year. The company earns $-27,190,000.00 in net income (profit) each year or ($17.58) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe.View Additional Information About Millendo Therapeutics.
What is Millendo Therapeutics' official website?
How can I contact Millendo Therapeutics?
Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MA, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]
MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
